Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

Abstract Background To evaluate the pharmacokinetic of plasma lopinavir (LPV) and ritonavir (RTV) when co-administered with three times weekly (TPW) rifabutin (RBT) at a dose of either 150 or 300 mg in African tuberculosis (TB) and HIV co-infected adult patients. Methods This is a pharmacokinetic st...

Full description

Bibliographic Details
Main Authors: Henri Gautier Ouedraogo, Alberto Matteelli, Giorgia Sulis, Tegwinde Rebeca Compaore, Serge Diagbouga, Simon Tiendrebeogo, Alberto Roggi, Kadari Cisse, Pier Francesco Giorgetti, Paola Villani, Lassana Sangare, Jacques Simpore, Mario Regazzi, Seni Kouanda
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Annals of Clinical Microbiology and Antimicrobials
Subjects:
Pharmacokinetic
Lopinavir
Ritonavir
Rifabutin
HIV–tuberculosis
Co-infection
Online Access:https://doi.org/10.1186/s12941-020-0345-6

Internet

https://doi.org/10.1186/s12941-020-0345-6

Similar Items